Vistin Pharma ASA
Manufacturing · Norway · 51-200 Employees
View Company Info for Free
Overview
Headquarters
Ostensjoveien 27, Oslo, Oslo, 0661, Norw...Phone Number
+47 35984200Website
www.vistin.comRevenue
$441.3 MillionStock Symbol
VISTINIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Vistin Pharma ASA
Vistin Pharma is a Norwegian pharmaceutical company specializing in the production of Metformin Hydrochloride, both as an active pharmaceutical ingredient (API) and direct compressible (DC) form. As a dedicated European Metformin producer, the company serves leading international pharmaceutical companies and aims to meet the growing global demand for diabetes medication. Vistin Pharma is committed to sustainability, with initiatives to balance business growth with environmental responsibility. The company is currently expanding its production capacity to enhance its supply capabilities while maintaining high-quality standards.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Vistin Pharma ASA your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Vistin Pharma ASA recently announced quarterly report
Product Launch: Get notified when Vistin Pharma ASA launches new products
Check out if Vistin Pharma ASA is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Check if Vistin Pharma ASA has recently received funding, and reach out quickly before it becomes old news!
Vistin Pharma ASA, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Vistin Pharma ASA had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Vistin Pharma ASA has new funding data
Congratulate Masked Content for being promoted to Masked Content at Vistin Pharma ASA
Recommended Actions
Find VP level buyers at Vistin Pharma ASA
Find more new buyers
Company Profile Activity
Activity Insights
Vistin Pharma ASA is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Vistin Pharma ASA is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Vistin Pharma ASA.
Vistin Pharma ASA Tech Stack
A closer look at the technologies used by Vistin Pharma ASA
Most Recent Scoops
Project
Vistin Pharma ASA has announced that its main distillation vessel has reached the end of its normal lifespan and will be replaced during an extended four-week biannual maintenance stop planned for Q4, covering both manufacturing lines, which is expected to impact production and sales volume in that quarter.
Facilities Maintenance, Manufacturing Operations
Earnings
Vistin Pharma ASA has reported that the average sales price for Q2 2026 was lower compared to Q2 2025, driven primarily by lower spot prices of metformin correlated with declining global raw material prices, as well as product mix changes and introductory pricing for new customers in new regions, with year-to-date revenue of NOK 212 million versus NOK 233 million last year and a gross margin of 66%.
Earnings
Vistin Pharma ASA has reported equity of approximately NOK 320 million as of H1 2026, compared to NOK 294.3 million for the same period last year, with net debt of approximately NOK 8 million at end of June 2026, total long-term liabilities of NOK 33.3 million versus NOK 22.3 million last year, and short-term liabilities of NOK 81 million versus NOK 105 million last year.
Accounting, Financial Reporting, Finance
Earnings
Vistin Pharma ASA has reported revenue of NOK 100 million for Q2 2026, a decrease compared to NOK 118 million in Q2 2025, driven by a significantly stronger Norwegian krone relative to the euro. Year-to-date revenue for H1 2026 ended at NOK 212 million, compared to NOK 233 million for the same period last year, representing a decrease of 9%.
Earnings, Finance
Earnings
Earnings, Finance
Vistin Pharma ASA News & Media
Vistin Pharma ASA: Invitation to Q2 2026 conference call
Oslo, Norway, 13 August 2026Vistin Pharma ASA: Minutes from the annual general meeting 2026
Oslo, Norway, 20 May 2026Disclosure of voting rights at AGM in Vistin Pharma ASA
Oslo, Norway, 20 May 2026
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Vistin Pharma ASA
Sign Up For FreeTo access detailed company insights
Vistin Pharma is a Norwegian pharmaceutical company specializing in the production of Metformin Hydrochloride, both as an active pharmaceutical ingredient (API) and direct compressible (DC) form. As a dedicated European Metformin producer, the company serves leading international pharmaceutical companies and aims to meet the growing global demand f... Read More
